Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial

Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul, Chaisith Sivakorn, Piengthong Narakorn, Somchaiya Surichan, Sumalee Prangpratanporn, Suttida Puksuriwong, Steven Lamola, Laina D Mercer, Rama Raghunandan, Weina Sun, Yonghong Liu, Juan Manuel Carreño, Rami Scharf, Weerapong Phumratanaprapin, Fatima Amanat, Luc Gagnon, Ching-Lin Hsieh, Ruangchai Kaweepornpoj, Sarwat Khan, Manjari Lal, Stephen McCroskery, Jason McLellan, Ignacio Mena, Marcia Meseck, Benjaluck Phonrat, Yupa Sabmee, Ratsamikorn Singchareon, Stefan Slamanig, Nava Suthepakul, Johnstone Tcheou, Narumon Thantamnu, Sompone Theerasurakarn, Steven Tran, Thanakrit Vilasmongkolchai, Jessica A White, Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Kittisak Poopipatpol, Ponthip Wirachwong, Richard Hjorth, Bruce L Innis
doi: https://doi.org/10.1101/2021.09.17.21263758

Article Information

doi 
https://doi.org/10.1101/2021.09.17.21263758
History 
  • September 22, 2021.

Article Versions

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Prof Punnee Pitisuttithum, MD1,
  2. Viravarn Luvira, MD1,
  3. Saranath Lawpoolsri, MD1,
  4. Sant Muangnoicharoen, MD1,
  5. Supitcha Kamolratanakul, MD1,
  6. Chaisith Sivakorn, MD1,
  7. Piengthong Narakorn, MS2,
  8. Somchaiya Surichan, PhD2,
  9. Sumalee Prangpratanporn, MS2,
  10. Suttida Puksuriwong, PhD2,
  11. Steven Lamola, MD3,
  12. Laina D Mercer, PhD3,
  13. Rama Raghunandan, PhD3,
  14. Weina Sun, PhD4,
  15. Yonghong Liu, PhD4,
  16. Juan Manuel Carreño, PhD4,
  17. Rami Scharf, DSc3,
  18. Weerapong Phumratanaprapin, MD1,
  19. Fatima Amanat, PhD4,
  20. Luc Gagnon, PhD9,
  21. Ching-Lin Hsieh, PhD10,
  22. Ruangchai Kaweepornpoj, MS2,
  23. Sarwat Khan, MS9,
  24. Manjari Lal, PhD3,
  25. Stephen McCroskery, MS4,
  26. Prof Jason McLellan, PhD10,
  27. Ignacio Mena, PhD4,5,
  28. Marcia Meseck, MS7,
  29. Benjaluck Phonrat, MS1,
  30. Yupa Sabmee, MS1,
  31. Ratsamikorn Singchareon, MS2,
  32. Stefan Slamanig, MS4,
  33. Nava Suthepakul, MS2,
  34. Johnstone Tcheou, BS4,
  35. Narumon Thantamnu, BS1,
  36. Sompone Theerasurakarn, MS2,
  37. Steven Tran, MS9,
  38. Thanakrit Vilasmongkolchai, MS2,
  39. Jessica A White, PhD3,
  40. Prof Adolfo Garcia-Sastre, PhD4,5,6,7,
  41. Prof Peter Palese, PhD4,6,
  42. Prof Florian Krammer, PhD4,8,
  43. Kittisak Poopipatpol, BS2,
  44. Ponthip Wirachwong, PhD2,
  45. Richard Hjorth, PhD3 and
  46. Bruce L Innis, MD3,*
  1. 1Faculty of Tropical Medicine, Mahidol University, Faculty of Tropical Medicine, Mahidol University 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400. Thailand
  2. 2The Government Pharmaceutical Organization, 1 Thanon Rama VI, Thung Phaya Thai, Ratchathewi, Bangkok 10400, Thailand
  3. 3PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA
  4. 4Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA
  5. 5Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA
  6. 6Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA
  7. 7The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA
  8. 8Department of Pathology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA
  9. 9Nexelis, 525 Bd Cartier O, Laval, QC H7V 3S8, Canada
  10. 10College of Natural Sciences, The University of Texas at Austin, 120 Inner Campus Dr Stop G2500, Austin, TX 78712, USA
  1. ↵*Correspondence to:
    Bruce L Innis, MD, PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA; binnis{at}path.org
Back to top
Posted September 22, 2021.
Download PDF
Data/Code
Email
Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial
Punnee Pitisuttithum, Viravarn Luvira, Saranath Lawpoolsri, Sant Muangnoicharoen, Supitcha Kamolratanakul, Chaisith Sivakorn, Piengthong Narakorn, Somchaiya Surichan, Sumalee Prangpratanporn, Suttida Puksuriwong, Steven Lamola, Laina D Mercer, Rama Raghunandan, Weina Sun, Yonghong Liu, Juan Manuel Carreño, Rami Scharf, Weerapong Phumratanaprapin, Fatima Amanat, Luc Gagnon, Ching-Lin Hsieh, Ruangchai Kaweepornpoj, Sarwat Khan, Manjari Lal, Stephen McCroskery, Jason McLellan, Ignacio Mena, Marcia Meseck, Benjaluck Phonrat, Yupa Sabmee, Ratsamikorn Singchareon, Stefan Slamanig, Nava Suthepakul, Johnstone Tcheou, Narumon Thantamnu, Sompone Theerasurakarn, Steven Tran, Thanakrit Vilasmongkolchai, Jessica A White, Adolfo Garcia-Sastre, Peter Palese, Florian Krammer, Kittisak Poopipatpol, Ponthip Wirachwong, Richard Hjorth, Bruce L Innis
medRxiv 2021.09.17.21263758; doi: https://doi.org/10.1101/2021.09.17.21263758
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area